Dengue Virus Gene Replikins Found Conserved and Shared in Current Dengue Strains Back to 1944 - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Dengue Virus Gene Replikins Found Conserved and Shared in Current Dengue Strains Back to 1944 New Analysis Provides Basis for a Synthetic Dengue Blocker-Vaccine Candidate Now Available for Testing


Dengue Virus Gene Replikins Found Conserved and Shared in Current Dengue Strains Back to 1944

New Analysis Provides Basis for a Synthetic Dengue Blocker-Vaccine Candidate Now Available for Testing

PR Newswire

LONDON, Aug. 26, 2014 /PRNewswire/ -- An analysis by Replikins, Ltd. of Pubmed data of the gene structures of all Dengue virus strains in Pubmed, has revealed extensive conservation and sharing of specific Replikin structures back to 1944. This conservation and sharing of specific Replikin gene structures has permitted the formulation of a Synthetic Dengue Blocker-Vaccine candidate, as it did for the H5N1 influenza vaccine and the Taura Syndrome Shrimp vaccine, both of which have been found to be effective (1,2).

This Dengue vaccine candidate is synthesized in five days and is available freeze-dried to governments and other institutions for testing and use according to the country's regulatory bodies.

For further information: Email 646-320-5910

References:

1. Jackwood et al. Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53:613-617, 2009.

2. Bogoch S and Bogoch ES. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1


SOURCE Replikins, Ltd.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here